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Summary
Objectives: It is unclear whether plasma homocysteine (Hcy) level affects long-
term outcomes in patients with previous percutaneous coronary intervention (PCI).
Accordingly, we investigated the association of plasma Hcy level with long-term
major adverse cardiovascular events (MACEs), especially with recurrence of angina
pectoris (AP) or new myocardial infarction (MI) in patients with previous PCI.
Methods: A total of 231 patients with previous (>12 months) PCI were followed up
for a median period of 49 months. The primary end point was recurrence of AP or
new MI. The secondary end points were MACEs (cardiovascular death, recurrence of
AP, new MI, revascularization therapy, hospitalization for heart failure, or stroke).
Results: During the follow-up period, 35 patients (15.2%) had a primary end point,
and 58 (25.1%) had a secondary end point. A univariate analysis by a Cox proportional
hazards regression model showed that plasma Hcy level was not associated with the
primary (hazard ratio [HR] 1.13, 95% conﬁdence interval [CI] 0.41—3.08, p = 0.82)
and secondary (HR 1.60, 95% CI 0.75—3.42, p = 0.23) end points. The adjustment for
other clinical variables did not alter the results.
Conclusions: Plasma Hcy level appears to be unrelated to recurrent AP, new MI, and
long-term MACE within coronary artery disease patients with previous PCI.
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omocysteine (Hcy) is a sulfhydryl-containing
mino acid derived from the demethylation of
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ethionine, one of the essential amino acids.
uCully ﬁrstly proposed a link between hyperho-
ocysteinemia and atherosclerotic diseases, based
n the ﬁndings of autopsies of children with
omocystinuria, an inborn error in methionine
etabolism [1]. Since a report [2] describing a
elationship between hyperhomocysteinemia and
oronary artery disease (CAD), the relationship
gy. Published by Elsevier Ireland Ltd. All rights reserved.
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Table 1 Baseline characteristics.
Number of patients 231
Age (years) 66± 8
Male 184 (79.7)
BMI (kg/m2) 24± 3
Current smoker 45 (19.5)
Family history of CAD 71 (30.7)
Previous MI 126 (54.5)
Multivessel disease 54 (23.4)
DM 90 (39.0)
Systolic blood pressure (mmHg) 118± 14
Diastolic blood pressure (mmHg) 68± 10
LDL cholesterol (mg/dL) 115± 28
HDL cholesterol (mg/dL) 45± 12
Triglycerides (mg/dL) 121± 58
Hcy (mol/L) 9.0 (7.5—11.3)
Estimated GFR (mL/min/1.73m2) 63± 17
CKD 101 (43.7)
LVEF (%) 60± 14
Methods of PCI
Balloon angioplasty 137 (59.3)
Bare-metal stent 82 (35.5)
Drug-eluting stent 0 (0)
Rotablation 12 (5.2)
Medications
Nitrates 177 (76.6)
Diuretics 50 (21.6)
Calcium antagonists 178 (77.1)
ACE inhibitors 65 (28.1)
Angiotensin II receptor blockers 38 (16.5)
Beta blockers 52 (22.5)
Statins 164 (71.0)
Values are expressed as mean± S.D., median (ﬁrst—third
quartiles), or number (%). BMI, body mass index; CAD, coro-
nary artery disease; MI, myocardial infarction; DM, diabetes
mellitus; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; Hcy, homocysteine; GFR, glomerular ﬁltration
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has been paid much attention [3]. Experimen-
tal studies have suggested that Hcy may promote
atherosclerosis through several mechanisms includ-
ing endothelial dysfunction [4], oxidation of
low-density lipoprotein [5,6], the activation of
inﬂammatory pathways [7], smooth muscle cell pro-
liferation [4,7], and the activation of coagulation
factors and platelets [4,7].
Previous studies have reported that the elevated
level of plasma Hcy is associated with a higher
incidence of restenosis after percutaneous coro-
nary intervention (PCI), although conﬂicting results
exist [8,9], and that patients with an elevated
level of plasma Hcy have an adverse short-term
outcome after PCI [10,11]. However, it is unclear
whether the plasma Hcy level affects long-term
outcomes in patients with previous PCI. Accord-
ingly, we sought to clarify the association of plasma
Hcy level with long-term major adverse cardiovas-
cular events (MACEs), especially with recurrence of
angina pectoris (AP) or new myocardial infarction
(MI) in patients with previous PCI.
Methods
Study population and data collection
Between August 1998 and March 2000, 231 patients
(184 men and 47 women, aged 66± 8 years) who
met the following criteria were enrolled in this
study: (1) patients with previous (>12 months)
PCI for at least one stenotic lesion in the native
coronary arteries, and (2) no restenosis of the
target lesions after PCI, which was conﬁrmed by
follow-up coronary angiography. Exclusion criteria
included age >80 years, acute coronary syndrome
within the preceding 12 months, severe symptoms
of congestive heart failure (New York Heart Associ-
ation functional class IV), concomitant idiopathic
myocardial diseases and vulvular heart diseases
requiring a cardiac operation, life-threatening
arrhythmias, hemodialysis or peritoneal dialysis,
malignancy, or severe chronic diseases. The study
protocol was approved by the ethics committee at
our institution, and informed consent was obtained
from each patient before the study.
Venous blood samples were drawn after an
overnight fast, and serum levels of creatinine,
low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, and triglycerides were
measured. Serum creatinine levels were mea-
sured by an enzyme method. Plasma total Hcy
levels were determined using a high-performance
liquid chromatography assay. Hyperhomocys-
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wrate; CKD, chronic kidney disease; LVEF, left ventricular ejec-
tion fraction; PCI, percutaneous coronary intervention; ACE,
angiotensin-converting enzyme.
einemia was deﬁned as a plasma Hcy level
f >15mol/L and was classiﬁed into the fol-
owing 3 groups: mild (15 <Hcy≤ 30mol/L);
oderate (30 <Hcy≤ 100mol/L); and severe
Hcy > 100mol/L) [12]. The estimated glomerular
ltration rate (eGFR) was calculated using the
odiﬁcation of diet in renal disease formula modi-
ed by the Japanese Society of Nephrology [13] and
as expressed as per 1.73m2 of the body surface
rea. Chronic kidney disease (CKD) was deﬁned
s an eGFR < 60mL/min/1.73m2 [14]. A 75-g oral
lucose tolerance test was performed if patients
ere not treated with oral hypoglycemic drugs
nd/or insulin. The patients whose fasting plasma
lucose level ≥126mg/dL and/or plasma glucose
evel ≥200mg/dL at 2 h after the glucose load
ere diagnosed as having diabetes mellitus (DM).
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eft ventricular ejection fraction was determined
y echocardiography and was calculated using a
odiﬁcation of Simpson’s rule [15].
he primary and secondary end points
he primary end point was recurrence of AP or new
I. The secondary end points were MACEs, including
ardiovascular death, recurrence of AP or new MI,
evascularization therapy, hospitalization for heart
ailure, and stroke. Cardiovascular deaths included
ny death for which there was no clearly docu-
ented non-cardiovascular cause.
tatistical analysis
ontinuous variables are presented as mean± S.D.
r median (ﬁrst—third quartiles). Categorical data
ere analyzed by the chi-square test. Compar-
sons of continuous data were performed using the
npaired t-test. The event-free rates for the pri-
ary and secondary end points between patients
ith a plasma Hcy level≥ the median value and
hose with a plasma Hcy level < the median value
ere estimated using the Kaplan—Meier method,
nd the event-free curves were then compared
sing the log-rank test. Univariate and multivari-
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Table 2 Baseline characteristics of patients with a plasma
with a plasma Hcy level <9.0mol/L.
Variables Hcy < 9.0mol/L (n
Age (years) 66± 7
Male 85 (73.9)
BMI (kg/m2) 25± 3
Current smoker 23 (20.0)
Family history of CAD 40 (34.8)
Previous MI 51 (44.3)
Multivessel disease 25 (21.7)
DM 48 (41.7)
Systolic blood pressure (mmHg) 118± 13
Diastolic blood pressure (mmHg) 69± 9
LDL cholesterol (mg/dL) 117± 27
HDL cholesterol (mg/dL) 46± 11
Triglycerides (mg/dL) 118± 49
Estimated GFR (mL/min/1.73m2) 69± 16
CKD 36 (31.3)
LVEF (%) 63± 13
Medications
Nitrates 88 (76.5)
Diuretics 19 (16.5)
Calcium antagonists 90 (78.3)
ACE inhibitors 28 (24.3)
Angiotensin II receptor blockers 18 (15.7)
Beta blockers 25 (21.7)
Statins 84 (73.0)
Data are presented as mean± S.D. or number (%). For abbreviationrdiovascular events 23
te analyses using a Cox proportional hazards
egression model were performed to determine
he predictors of the primary and secondary end
oints. A multivariate analysis was performed using
ariables that showed p≤ 0.2 in the univariate anal-
ses. Logarithmically transformed Hcy values were
sed in these analyses in order to ensure a normal
istribution. A p-value < 0.05 was considered to be
tatistically signiﬁcant. Data analysis was carried
ut using SPSS 12.0J for Windows (SPSS Inc., Tokyo,
apan).
esults
he median follow-up period was 49 months.
aseline characteristics of the study population
re shown in Table 1. The prevalence of DM,
revious MI, multivessel disease, and CKD was
9.0%, 54.5%, 23.4%, and 43.7%, respectively.
he low-density lipoprotein cholesterol level was
15± 28mg/dL. Nitrates, diuretics, calcium antag-
nists, angiotensin-converting enzyme inhibitors,
ngiotensin receptor blockers, beta blockers, and
tatins were administered to 76.6%, 21.6%, 77.1%,
8.1%, 16.5%, 22.5%, and 71.0% of the study popula-
ion, respectively. Balloon angioplasty, bare-metal
Hcy level ≥9.0mol/L (the median value) and those
= 115) Hcy≥ 9.0mol/L (n = 116) p-Value
67± 8 0.83
99 (85.3) 0.03
24± 3 0.07
22 (19.0) 0.84
31 (26.7) 0.18
75 (64.7) <0.01
29 (25.0) 0.55
42 (36.2) 0.38
118± 15 0.79
68± 10 0.64
114± 29 0.37
44± 12 0.22
124± 66 0.45
58± 16 <0.01
65 (56.0) <0.01
57± 15 0.03
89 (76.7) 0.97
31 (26.7) 0.07
88 (75.9) 0.66
37 (31.9) 0.20
20 (17.2) 0.74
27 (23.3) 0.78
80 (69.0) 0.49
s, see Table 1.
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e rates for the primary (A) and secondary (B) end points
vel of ≥9.0mol/L and those with a plasma Hcy level of
Table 4 shows the results of univariate and
multivariate analyses by a Cox proportional haz-
ards model performed to determine the predictors
of the primary and secondary end points. On
univariate analyses, logHcy was not associated
with the primary (hazard ratio [HR] 1.13, 95%
conﬁdence interval [CI] 0.41—3.08, p = 0.82) and
secondary (HR 1.60, 95% CI 0.75—3.42, p = 0.23)
end points. The adjustment for other clinical
variables shown in Table 4 did not alter the results
(primary end point: HR 1.15, 95% CI 0.34—3.90,
p = 0.82; secondary end point: HR 1.35, 95% CI
0.54—3.36, p = 0.52). On univariate analyses, DM
was signiﬁcantly associated with the primary and
secondary end points, and CKD was signiﬁcantly
Table 3 Incidence of the primary and secondary end
points.
Primary end point 35 (15.2)
Recurrence of AP or new MI 35 (15.2)
Secondary end point 58 (25.1)
Recurrence of AP or new MI 35 (15.2)
Cardiovascular death 5 (2.2)
Hospitalization for heart failure 9 (3.9)Figure 1 Kaplan—Meier curves of cumulative event-fre
between patients with a plasma homocysteine (Hcy) le
<9.0mol/L.
stenting, and rotablation were undergone in
59.2%, 35.5%, and 5.2% of the study population,
respectively. No patients underwent drug-eluting
stenting.
The median Hcy level was 9.0mol/L, and 210
patients (90.9%) had a normal plasma Hcy level.
Mild and moderate hyperhomocysteinemia were
observed in 20 (8.7%) and 1 (0.4%) of the patients
studied, respectively. None of the patients had
severe hyperhomocysteinemia. Table 2 shows base-
line characteristics of patients with a plasma Hcy
level ≥9.0mol/L and those with a plasma Hcy
level <9.0mol/L. Patients with a plasma Hcy level
≥9.0mol/L had higher frequencies of male gen-
der, previous MI, and CKD than those with a plasma
Hcy level <9.0mol/L. The former had a lower
eGFR and LVEF than the latter.
Table 3 shows the incidence of the primary and
secondary end points during the follow-up period.
Thirty-ﬁve patients (15.2%) and 58 patients (25.1%)
had primary and secondary end points, respec-
tively. Of the latter patients, 5 (2.2%) died of
cardiovascular causes, 9 (3.9%) were hospitalized
for heart failure, 38 (16.5%) underwent revascu-
larization therapy, and 5 (2.2%) had a stroke. The
Kaplan—Meier curves showed no signiﬁcant dif-
ferences in the event-free rates of primary and
secondary end points between patients with a
plasma Hcy level of ≥9.0mol/L and those with a
plasma Hcy level of <9.0mol/L (Fig. 1).
Revascularization therapy 38 (16.5)
Stroke 5 (2.2)
Data are presented as number (%). AP, angina. For another
abbreviation, see Table 1.
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Table 4 Univariate and multivariate analyses using a Cox proportional hazards model in order to determine the predictors of the primary and secondary end
points.
Variables Primary end point Secondary end point
Univariate Multivariate Univariate Multivariate
HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
Age (years) 1.01 (0.97—1.06) 0.61 1.02 (0.99—1.06) 0.22
Male 1.17 (0.49—2.82) 0.73 1.05 (0.54—2.02) 0.89
BMI (kg/m2) 1.08 (0.98—1.19) 0.14 1.06 (0.96—1.18) 0.24 1.04 (0.96—1.13) 0.35
Current smoker 1.21 (0.64—1.21) 0.22 1.07 (0.57—2.03) 0.83
Family history of CAD 0.96 (0.46—2.00) 0.91 0.83 (0.46—1.49) 0.52
Previous MI 0.99 (0.51—1.93) 0.98 0.92 (0.55—1.55) 0.77
Multivessel disease 1.38 (0.66—2.88) 0.39 1.21 (0.67—2.17) 0.53
DM 2.28 (1.17—4.45) 0.02 2.03 (1.02—4.03) 0.04 2.19 (1.30—3.69) <0.01 2.12 (1.23—3.65) <0.01
Systolic blood pressure
(mmHg)
0.99 (0.97—1.02) 0.62 1.01 (0.97—1.03) 0.37
Diastolic blood pressure
(mmHg)
0.99 (0.96—1.03) 0.65 1.00 (0.97—1.03) 0.83
LDL cholesterol (mg/dL) 1.00 (0.99—1.02) 0.50 1.01 (0.99—1.02) 0.29
HDL cholesterol (mg/dL) 1.00 (0.97—1.03) 0.80 0.99 (0.97—1.01) 0.28
Triglycerides (mg/dL) 1.00 (0.99—1.01) 0.14 1.00 (0.99—1.01) 0.48 1.00 (0.99—1.01) 0.29
LogHcy (mol/L) 1.13 (0.41—3.08) 0.82 1.60 (0.75—3.42) 0.23
CKD 1.18 (0.60—2.30) 0.64 1.79 (1.07—3.01) 0.03 1.77 (1.04—3.01) 0.04
LVEF (%) 1.00 (0.98—1.03) 0.76 0.99 (0.98—1.01) 0.41
Nitrates 0.93 (0.43—1.98) 0.84 1.38 (0.72—2.67) 0.33
Diuretics 0.89 (0.39—2.03) 0.78 1.24 (0.69—2.22) 0.48
Calcium antagonists 1.40 (0.48—4.01) 0.53 1.18 (0.55—2.51) 0.67
ACE inhibitors 1.14 (0.56—2.33) 0.72 1.52 (0.89—2.58) 0.12 1.17 (0.67—2.04) 0.59
Angiotensin II receptor
blockers
0.99 (0.23—4.32) 0.99 1.35 (0.52—3.51) 0.54
Beta blockers 1.65 (0.77—3.54) 0.20 1.59 (0.73—3.47) 0.24 1.48 (0.81—2.72) 0.20 1.30 (0.70—2.39) 0.40
Statins 1.19 (0.56—2.53) 0.66 1.41 (0.76—2.61) 0.28
HR, hazard ratio; CI, conﬁdence interval. For other abbreviations, see Table 1
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associated with the secondary end point. On a
multivariate analysis, DM was an independent
predictor of the primary and secondary end points
(HR 2.03, 95% CI 1.02—4.03, p = 0.04, and HR 2.12,
95% CI 1.23—3.65, p < 0.01, respectively), and CKD
was an independent predictor of the secondary
end point (HR 1.77, 95% CI 1.04—3.01, p = 0.03).
Discussion
The major ﬁndings of the present study are as fol-
lows: in patients with previous PCI, (1) the plasma
Hcy level was not associated with recurrence of AP
or new MI and long-term MACEs; (2) DM was an inde-
pendent predictor of recurrence of AP or new MI and
long-term MACEs; and (3) CKD was an independent
predictor of long-term MACEs.
Plasma Hcy levels and the long-term
outcome in patients with previous PCI
Previous studies have reported that patients with
an elevated level of plasma Hcy have an adverse
short-term outcome after PCI [10,11]. However, it
has not been clariﬁed whether plasma Hcy level
affects long-term outcomes in patients with previ-
ous PCI. The present study found no associations of
plasma Hcy levels with long-term adverse outcomes
in patients with previous PCI.
Early cross-sectional and retrospective stud-
ies have indicated a positive association between
plasma Hcy levels and CAD [3]. However, recent
prospective studies have indicated that plasma
Hcy levels have only a weak association with CAD
[16,17]. A recent meta-analysis [18] showed that
the odds ratios for CAD in a 5-mol/L increment of
plasma Hcy level were 1.06 (95% CI 0.99—1.13) in
cohort studies, 1.23 (95% CI 1.07—1.41) in nested
case-control studies, and 1.70 (95% CI 1.50—1.93)
in case-control studies. More recently, the prospec-
tive epidemiological study of myocardial infarction
study showed no association between plasma Hcy
levels and future coronary events including non-
fatal MI, death from CAD, or angina pectoris
in 10,593 men without CAD [19]. Furthermore,
prospective large clinical trials could not ﬁnd that
Hcy-lowering therapy with folic acid, vitamin B12,
and vitamin B6 reduces the incidence of future car-
diovascular events in patients with acute MI [20]
and stable CAD [21]. Thus, the status of plasma
Hcy level as a risk factor for CAD has not yet been
established [22].
Renal function is well known to affect plasma
Hcy levels [23]. Muntner et al. [24] reported
that the frequencies of hyperhomocysteine-
S
T
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ia were 32.9% of persons with a GFR of
5—59mL/min/1.73m2 and 6.1% of persons
ith a GFR of 60—89mL/min/1.73m2. In the
resent study, patients with a plasma Hcy level
9.0mol/L had a lower eGFR than those with a
lasma Hcy level <9.0mol/L. Therefore, renal
unction should be taken into consideration when
nvestigating the relationship between plasma Hcy
evels and cardiovascular events. Menon et al.
25] reported that the plasma Hcy level was not
ssociated with all-causes or cardiovascular deaths
fter the adjustment for GFR in 804 patients with
KD. It is well known that CKD is an important
isk factor for future cardiovascular events [26].
he present study also demonstrated that CKD
as an independent predictor of long-term MACEs
n patients with previous PCI. The association
etween plasma Hcy levels and future cardio-
ascular events having been previously reported
ay have indirectly represented an association
etween renal dysfunction and future cardio-
ascular events. Further studies are needed to
larify whether hyperhomocysteinemia is indeed
ssociated with adverse cardiovascular outcomes
ndependent of renal function.
M and the long-term outcome in patients
ith previous PCI
revious studies have demonstrated that patients
ith DM have a 2—3-fold risk of future cardiovas-
ular events than non-diabetics [27,28] and that
iabetic patients have adverse short- and long-
erm outcomes after PCI [29—31]. The present
tudy also showed that DM is an independent
redictor of long-term adverse outcomes in CAD
atients with previous PCI. Several mechanisms
or an association between DM and the adverse
utcomes are considered. Coronary atheroscle-
otic disease is more advanced in diabetic patients
han non-diabetic patients [31—33], and diabetic
atients with CAD often have multiple vulnerable
laques [34] that would be associated with future
cute coronary syndrome. Pathophysiologically,
n diabetic patients, the metabolic abnormali-
ies including hyperglycemia, increased free fatty
cids, and insulin resistance provoke molecular
echanisms that alter the function and structure
f blood vessels [35], leading to the progression of
therosclerosis and subsequently increasing risk of
dverse cardiovascular events.trengths of the present study
he strengths of the present study are as follows.
irst, the presence or absence of stenotic lesions
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[lasma homocysteine level is unrelated to long-term
n the coronary arteries was evaluated by coronary
ngiography in all patients. Second, the present
tudy included only stable CAD patients with pre-
ious PCI who did not developed restenosis of the
arget lesion after PCI, which was conﬁrmed by
ollow-up coronary angiography. Third, the target
esion for recurrent AP or new MI was conﬁrmed by
oronary angiography in all patients except those
ith sudden death.
imitations of the present study
he present study has certain limitations. First,
he sample size of the present study was relatively
mall. Second, in the present study, the preva-
ence of hyperhomocysteinemia was only 9.1%, and
5% of patients with hyperhomocysteinemia had
ild hyperhomocysteinemia. This might be partly
ecause patients with a serum creatinine level
2.5mg/dL were not included in the present study:
e do not generally perform coronary angiogra-
hy or PCI for those patients who do not undergo
hronic dialysis. As renal insufﬁciency is an impor-
ant risk factor for the elevated level of plasma
cy [24], a lack of patients with a serum creati-
ine level >2.5mg/dL may have been associated
ith a low prevalence of hyperhomocysteinemia in
he present study. Finally, although it was recently
eported that the plasma free Hcy level but not the
lasma total Hcy level is an independent risk fac-
or for recurrent cardiovascular events in patients
ospitalized for acute coronary syndrome [36], we
id not measure the plasma free Hcy level.
onclusions
he plasma Hcy level appears to be unrelated to
ecurrent AP, new MI, and long-term MACEs in CAD
atients with previous PCI.
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